Your session is about to expire
← Back to Search
Gene Editing
CTX001 for Sickle Cell Disease and Thalassemia
Phase 3
Recruiting
Research Sponsored by Vertex Pharmaceuticals Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Pivotal Trial
No Placebo-Only Group
Summary
This trial tests a new treatment where a patient's own blood stem cells are modified to fix faulty genes. It targets patients with severe blood disorders who need frequent transfusions. The goal is to help their bodies produce healthy blood cells. Recent advances in treatment methods expand the potentially curative options for patients.
Who is the study for?
This trial is for individuals with transfusion-dependent β-thalassemia or severe sickle cell disease who are eligible for a stem cell transplant. It's not open to those with prior transplants, available matched donors, certain genetic conditions like α-thalassemia in TDT patients, or untreated moyamoya syndrome in SCD patients.
What is being tested?
The study tests CTX001, which involves editing the patient's own stem cells using CRISPR-Cas9 technology and then returning them to the body. The goal is to see if this single-dose treatment can safely improve symptoms of these blood disorders.
What are the potential side effects?
Potential side effects may include typical risks associated with stem cell transplants such as infection risk due to immune suppression during conditioning, possible infusion reactions, and complications from the gene-editing process.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: CTX001Experimental Treatment1 Intervention
CTX001 (autologous CD34+ hHSPCs modified with CRISPR-Cas9 at the erythroid lineage-specific enhancer of the BCL11A gene). Participants will receive a single infusion of CTX001 through a central venous catheter.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for hemoglobin disorders include hydroxyurea, hematopoietic stem cell transplantation (HSCT), and gene therapy. Hydroxyurea works by increasing fetal hemoglobin production, which reduces the sickling of red blood cells in sickle cell disease (SCD).
HSCT involves replacing the patient's defective stem cells with healthy donor cells, which can cure the disease but comes with significant risks and accessibility issues. Gene therapy, particularly using CRISPR-Cas9 as in the CTX001 trial, involves editing the patient's own hematopoietic stem cells to correct the genetic mutation causing the disorder.
This approach aims to provide a long-term cure with fewer complications compared to HSCT. These mechanisms are crucial for patients as they offer potential curative options, improving quality of life and reducing disease-related complications.
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.Hematopoietic stem cell transplantation for Gaucher disease.
Curative therapy for hemoglobinopathies: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo stem cell gene therapy versus allogeneic hematopoietic stem cell transplantation.Highly efficient editing of the β-globin gene in patient-derived hematopoietic stem and progenitor cells to treat sickle cell disease.Hematopoietic stem cell transplantation for Gaucher disease.
Find a Location
Who is running the clinical trial?
Vertex Pharmaceuticals IncorporatedLead Sponsor
256 Previous Clinical Trials
34,979 Total Patients Enrolled
CRISPR TherapeuticsIndustry Sponsor
6 Previous Clinical Trials
602 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have TDT with specific genetic changes or sickle cell β-thalassemia.I have sickle cell disease and moyamoya syndrome that hasn't been treated.I am considered suitable for a stem cell transplant by my doctor.I have severe sickle cell disease and have had at least two severe pain crises per year for the last two years.I have been diagnosed with TDT and need regular blood transfusions.I have severe sickle cell disease with at least two pain crises per year for the last two years.I have been diagnosed with TDT and need regular blood transfusions.
Research Study Groups:
This trial has the following groups:- Group 1: CTX001
Awards:
This trial has 2 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger